CAPR - Capricor Therapeutics, Inc.
About Capricor Therapeutics, Inc. (https://www.capricor.com)
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Anthony J. Bergmann | Chief Financial Officer & Corporate Treasurer | 1986 | $584,750 USD |
| Linda Marbán | Co-Founder, President, Chief Executive Officer & Director | 1963 | $580,645 USD |
| Karen G. Krasney | Executive Vice President, General Counsel & Secretary | 1953 | $500,718 USD |
| Frank Isaac Litvack FACC | Executive Chairman of the Board | 1956 | $120,000 USD |
| Catherine Lee Kelleher | Consultant | – | – |
| Kristi A. H. Elliott | Chief Operating & Science Officer | – | – |
| Mark Awadalla | Chief Development Officer | – | – |
| Micheal Binks | Chief Medical Officer | – | – |
| Minghao Sun | Senior Vice President of Quality Control, Research & Product Development | – | – |
| Nathaniel Hogan | Director of Biostatistics of Capricor Therapeutics | – | – |